BTIG Reaffirms Their Sell Rating on Ginkgo Bioworks Holdings (DNA)
In a report released yesterday, Mark Massaro from BTIG reiterated a Sell rating on Ginkgo Bioworks Holdings (DNA – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $7.77.
Light Up your Portfolio with Spark:
- Easily identify stocks' risks and opportunities.
- Discover stocks' market position with detailed competitor analyses.
According to TipRanks, Massaro is an analyst with an average return of -7.9% and a 28.98% success rate. Massaro covers the Healthcare sector, focusing on stocks such as NeoGenomics, Zoetis, and Natera.
Currently, the analyst consensus on Ginkgo Bioworks Holdings is a Moderate Sell with an average price target of $9.17.
DNA market cap is currently $404.5M and has a P/E ratio of -0.73.
Read More on DNA:
Questions or Comments about the article? Write to editor@tipranks.com- Ginkgo Bioworks Holdings: Balancing Growth and Uncertainty with a Hold Rating
- Largest borrow rate increases among liquid names
- Ginkgo Bioworks Earnings Call: Mixed Sentiments and Strategic Moves
- Sell Rating on Ginkgo Bioworks: Concerns Over Revenue Forecast, Operational Challenges, and Risk Profile
- Ginkgo Bioworks falls -12.5%
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.